Compare · ASTC vs BIO
ASTC vs BIO
Side-by-side comparison of Astrotech Corporation (DE) (ASTC) and Bio-Rad Laboratories Inc. (BIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ASTC and BIO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $9.75B, about 933.7x ASTC ($10.4M).
- Over the past year, ASTC is up 8.4% and BIO is up 13.6% - BIO leads by 5.2 points.
- ASTC has been more active in the news (10 items in the past 4 weeks vs 1 for BIO).
- BIO has more recent analyst coverage (12 ratings vs 0 for ASTC).
- Company
- Astrotech Corporation (DE)
- Bio-Rad Laboratories Inc.
- Price
- $4.79-7.09%
- $353.60-3.03%
- Market cap
- $10.4M
- $9.75B
- 1M return
- -23.87%
- -7.58%
- 1Y return
- +8.38%
- +13.58%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 1980
- News (4w)
- 10
- 1
- Recent ratings
- 0
- 12
Astrotech Corporation (DE)
Astrotech Corporation operates as a science and technology development and commercialization company worldwide. It operates through three segments, Astrotech Technologies, Inc. (ATI), 1st Detect Corporation (1st Detect), and AgLAB Inc (AgLAB). The ATI segment owns and licenses the AMS Technology, the platform mass spectrometry technology. The 1st Detect segment manufactures explosives and narcotics trace detectors for use at airports, secured facilities, and borders. This segment provides TRACER 1000, a mass spectrometer based explosives trace detector to replace the explosives trace detectors used at airports, cargo and secured facilities, and borders. The AgLAB segment develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. It also develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. Astrotech Corporation was incorporated in 1984 is based in Austin, Texas.
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Latest ASTC
- Director Kreps Matthew was granted 1,114 shares, increasing direct ownership by 52% to 3,264 units (SEC Form 4)
- Director Winn Charles Arch was granted 1,331 shares, increasing direct ownership by 10% to 14,431 units (SEC Form 4)
- Director Halinski John William was granted 1,331 shares, increasing direct ownership by 11% to 13,542 units (SEC Form 4)
- Director Stober Eric was granted 1,473 shares, increasing direct ownership by 7% to 21,127 units (SEC Form 4)
- Director Mcfarland Robert N was granted 1,331 shares, increasing direct ownership by 6% to 22,292 units (SEC Form 4)
- Director Wilkinson Tom was granted 1,331 shares, increasing direct ownership by 4% to 32,254 units (SEC Form 4)
- SEC Form 10-K filed by Astrotech Corporation (DE)
- Astrotech Corporation (DE) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Astrotech Reports Fiscal Year 2026 Financial Results
- Innventure Leadership Increases Focus on Accelsius Value Creation, Implements Significant Cost Cuts, and Strengthens Board Independence
Latest BIO
- Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
- Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
- Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference
- IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
- Bio-Rad Reports Second-Quarter 2026 Financial Results
- Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026